PRA Health Sciences downgraded by Baird with a new price target
$PRAH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00
Save time and jump to the most important pieces.
4 - PRA Health Sciences, Inc. (0001613859) (Issuer)
4 - PRA Health Sciences, Inc. (0001613859) (Issuer)
4 - PRA Health Sciences, Inc. (0001613859) (Issuer)
Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e
NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker
Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re
SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)
SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)
SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)
S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)
S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)
S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)
Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously
Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously
Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in